Administration of therapeutics with anti-FCRH5 / anti-CD3 bispecific antibodies

CN119487067APending Publication Date: 2025-02-18GENENTECH INC
View PDF 180 Cites 0 Cited by

Patent Information

Application Number
CN202280094390.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-04-01
Publication Date
2025-02-18

Smart Images

  • Figure GDA0005237279540000441
    Figure GDA0005237279540000441
  • Figure GDA0005237279540001191
    Figure GDA0005237279540001191
  • Figure GDA0005237279540001201
    Figure GDA0005237279540001201
Patent Text Reader

Abstract

The present invention provides methods of administration for treating cancer, such as multiple myeloma, with an anti-crystallizable fragment receptor-like 5 (FcRH5) / anti-cluster of differentiation 3 (CD3) bispecific antibody.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof

    EP0404097A2

  • Cytotoxic agents comprising maytansinoids and their therapeutic use

    EP0425235B1

  • Process for purifying antibody

    US20020164328A1

  • Antibody composition-producing cell

    US20030115614A1

  • Glycoprotein compositions

    US20030157108A1